Combined gonadotropin therapy to replace mini-puberty in male infants with congenital hypogonadotropic hypogonadism.

Infants with severe congenital hypogonadotropic hypogonadism lack both pubertal development in adolescence and infantile mini-puberty.

• Mini-puberty is characterized by gonadotropin and sex steroid concentrations rising into the adult range during infancy.
• The condition results from severe central disorders of the hypothalamic-pituitary-gonadal axis leading to gonadotropin deficiency.
• The deficiency occurs in both congenital hypogonadotropic hypogonadism and multiple pituitary hormone deficiency.

Mini-puberty is described as vital for future reproductive capacity, particularly in boys.

• The paper characterizes mini-puberty as a critical developmental window for reproductive capacity.
• Boys are specifically highlighted as being particularly affected by the absence of mini-puberty.
• There is currently no consensus on diagnosis or management of infants with gonadotropin deficiency.

Gonadotropin treatment in male infants with absent mini-puberty is effective in promoting testicular descent in those with undescended testes.

• Evidence is derived from case series.
• The treatment targets replacement of the absent mini-puberty period.
• Combined gonadotropin therapy is the treatment modality described.

Gonadotropin treatment facilitates increased penile size in male infants with congenital hypogonadotropic hypogonadism.

• Evidence comes from case series data.
• Penile growth is described as an outcome of gonadotropin replacement therapy during the mini-puberty window.
• This represents one of the key measurable clinical endpoints of treatment.

FSH replacement increases the testicular Sertoli cell population in male infants with gonadotropin deficiency.

• The increase in Sertoli cell population is measurable as an increase in testicular volume and inhibin B.
• This hypothetically increases the capacity for spermatogenesis in adult life for these patients.
• Follicle-stimulating hormone (FSH) is identified as the specific component responsible for this effect.

Long-term follow-up data is limited for outcomes pertaining to both fertility and non-reproductive sequelae.

• Non-reproductive sequelae specifically identified as understudied include neurodevelopment and psychological well-being.
• The paper identifies this as a significant gap in current knowledge.
• The use of international registries for patients with gonadotropin deficiency is described as a key element to address this gap.

International registries are identified as a key element for collecting high-quality, geographically widespread data to inform best-practice management.

• Registries are proposed to inform management from birth to adulthood.
• The need for geographically widespread data collection is emphasized.
• Registry data is positioned as necessary to address the absence of consensus on diagnosis and management.